Transgenomic's Proprietary Clopidogrel (Plavix() Response Panel Includes Both Genetic Markers Demonstrated to Be Significant in Third Independent Study

Transgenomic, Inc. (OTCBB: TBIO) today announced the publication of a new study by researchers at Vanderbilt University that further validates the role of both genes found in the Company's PGxPredict ® :CLOPIDOGREL (Plavix ® ) Panel, a comprehensive test to predict a patient's response to clopidogrel (Plavix ® ). The study confirms the results of two previous studies demonstrating that outcomes in patients receiving clopidogrel were better for patients without genetic va...continued TBIO  clia Electronics laboratory

URL: http://www.investorpoint.com/news/OTCBULLB/48961108/